The round, led by Headline with participation from Village Global, TA Ventures, Operator Partners, and Correlation Ventures, also adds Headline cofounder Mathias Schilling to the board. 

“We’ve been very intentional and disciplined around capital raising,” founder and CEO John Zhao told Fortune, noting that all of Blossom’s rounds were oversubscribed but that the company “could raise more, but we choose not to.” Capital, he added, “is both a weapon and a liability.”

Zhao, who previously worked at two hyperscale startups—Athelas, now a multibillion‑dollar company, and online insurance marketplace EverQuote, which he helped scale through an IPO—frames Blossom as a chance to build a “generational company” in mental health. “As long as there are human beings, we’re going to need healthcare, and mental health is only a larger and larger component of each person’s holistic health,” he said.

Blossom’s timing, he sees as a counterpoint to the perception that digital mental health has already been solved by the last wave of teletherapy and telehealth platforms. Those platforms, Zhao described as “ill‑equipped or nonexistent” in the psychiatry space.

Blossom markets itself as an “all‑in‑one AI copilot” that both augments psychiatrists’ clinical decisions and automates the back office tasks that typically bog down an in‑network practice. That means turning what Zhao describes as historically “extremely episodic” care into a continuous relationship driven by AI agents that text patients between visits, help surface warning signs, and tee up information for clinicians. He pointed to a postpartum depression case, where instead of waiting a month until the next visit, Blossom follows up with conversational check‑ins on sleep and mood, “just like texting a therapist,” rather than relying on static questionnaires. In general, most patients on the platform are seen in under 48 hours, oftentimes same-day. 

Zhao is blunt that AI in health care will only work if clinicians buy in. “It starts with listening to clinicians—and not just listening, but involving them in the creation of all our AI products every step of the way,” he said, noting that Blossom’s clinical director and “100‑plus clinicians” pilot features before they roll out more broadly.

He draws a sharp line between clinical tools and support agents, however. “These are ways we help clinicians treat patients more confidently, accurately, and effectively,” Zhao told Fortune. Everything else—billing, scheduling, dealing with insurers and pharmacies—is handled by agents that replace what he describes as the “army of people” it used to take to run a clinic.

Blossom says its tools are already used by hundreds of clinicians treating more than 10,000 patients across multiple states, and it markets in‑network coverage with major insurers and average copays around $22. The company pitches itself against a backdrop in which roughly one in four U.S. adults experience a mental health condition in a given year, and more than 28 million adults with mental illness receive no treatment at all.

Zhao’s ambition is to turn Blossom into the “destination of choice” in psychiatry, analogous to a JPMorgan Chase in retail banking, with concrete plans to expand well beyond the nine states it currently serves in the near future, deepen payer relationships, and keep investing in applied AI R&D. “Previously, scale was something that broke healthcare companies,” Zhao said. “Now we’ve flipped that paradigm on its head. The more we grow, the better we are at helping our doctors and helping our patients.”